Anti-MMP-1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the hemopexin domain of human MMP-1 (interstitial collagenase, UniProt P03956), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Rat, Pan, Monkey, Dog, Pig
UniProt
P03956
Size
100ug
Cat. #
RP2MMP1

In stock

SKU
RP-MMP1

Options

As low as: $130.00

Target Overview

Matrix metalloproteinase-1 (MMP-1, EC 3.4.24.7), also known as interstitial collagenase or fibroblast collagenase, is a secreted zinc-dependent endopeptidase that degrades fibrillar collagens in the extracellular matrix. The 469-amino acid protein (UniProt P03956) is synthesized as a zymogen and activated by proteolytic removal of the N-terminal propeptide. MMP-1 cleaves types I, II, and III collagen at a single site within the triple-helical domain, generating characteristic three-quarter and one-quarter fragments. It also processes types VII and X collagen. MMP-1 is expressed by fibroblasts, keratinocytes, macrophages, and endothelial cells in response to inflammatory cytokines, growth factors, and tumor promoters. The enzyme contains a catalytic domain and a C-terminal hemopexin-like domain required for substrate recognition and collagenolytic activity. MMP-1 plays central roles in tissue remodeling, wound healing, angiogenesis, and tumor invasion, and is implicated in arthritis, fibrosis, cancer metastasis, and cardiovascular disease. In the context of HIV infection, MMP-1 cleaves secreted viral Tat protein, reducing neurotoxicity.

Background

MMP-1 is the prototypical member of the matrix metalloproteinase family and was the first mammalian collagenase identified. Its primary physiological function is the degradation of interstitial collagens, particularly types I, II, and III, which are major structural components of connective tissue. Unlike most proteases that denature collagen before cleavage, MMP-1 cleaves native triple-helical collagen at neutral pH, initiating a cascade of matrix degradation by exposing cleavage products to further proteolytic attack by gelatinases and other MMPs. Activity is tightly regulated at the transcriptional level and by endogenous tissue inhibitors of metalloproteinases (TIMPs). Dysregulated MMP-1 expression is observed in multiple pathological contexts: overexpression contributes to cartilage destruction in rheumatoid arthritis and osteoarthritis, promotes tumor invasion and metastasis in breast, lung, and colorectal cancers, and drives pathological remodeling in atherosclerosis and aneurysm formation. Recent studies continue to expand the understanding of MMP-1 in disease. Tian et al (2026) identified peptides from Camelus bactrianus placenta that inhibit MMP-1 activity and explored their potential anti-skin aging effects through network pharmacology and in vitro validation. Borikun et al (2026) reported stress-induced changes in Mmp1 gene methylation in rat tumor models, suggesting epigenetic regulation of MMP-1 in cancer progression. Wang et al (2026) identified MMP-1 as a potential biomarker in kidney stone disease through integrated transcriptomic and proteomic profiling. These findings underscore the continued relevance of MMP-1 as both a therapeutic target and a diagnostic marker across diverse tissue pathologies. Triple Point Biologics offers multiple rabbit polyclonal antibodies raised against the hemopexin domain of human MMP-1, validated for Western blot applications. Reactivity has been confirmed in human samples, with predicted cross-reactivity in rat, primate, dog, and pig based on sequence homology.

References

  1. Tian L et al (2026) Targeted discovery of anti-skin aging peptides from Camelus bactrianus placenta: Multi-activity screening, network pharmacology, and in vitro validation focusing on MMP-1 inhibition. J Ethnopharmacol. PubMed · doi:10.1016/j.jep.2026.122064
  2. Borikun T et al (2026) Stress-Induced Changes in the Methylation Status of Mmp1 and Mmp8 Genes in Tumor Tissue of Rats with Guerin Carcinoma. Exp Oncol. PubMed · doi:10.15407/exp-oncology.2026.01.046
  3. Wang N et al (2026) Identification of Biomarker in Kidney Stone Disease by Integrating Transcriptomics and Olink Proteomics: A Case-Control Study. J Inflamm Res. PubMed · doi:10.2147/JIR.S605025

Additional Specifications

Gene Symbol MMP1
UniProt ID P03956
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Rat, Pan, Monkey, Dog, Pig
Pack Size 100ug
Immunogen (Full-length recombinant human protein)Full-length recombinant human MMP-1 protein. Immunogen is proprietary and confidential.
Immunogen (Hemopexin domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 269-469.
Immunogen (Hinge region)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 250-274.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 419-469.
Immunogen (Â Aminoterminal end of active enzyme)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 100-150.
Immunogen (Propeptide region)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 20-99.
Alternate Names MMP-1, MMP1, Interstitial collagenase, Fibroblast collagenase, Matrix metalloproteinase-1, EC 3.4.24.7, CLG, Collagenase-1

Frequently Asked Questions

What molecular weight should I expect for MMP-1 on a Western blot?

MMP-1 migrates as multiple bands corresponding to its activation states. The full-length proenzyme runs at approximately 52-57 kDa, while the catalytically active form, generated after removal of the N-terminal propeptide, appears at approximately 41-45 kDa. You may detect both forms simultaneously depending on your sample type and experimental conditions. Cell lysates often show primarily the zymogen, whereas conditioned media from stimulated cells or tissue extracts exposed to activating proteases will display both pro- and active forms. Glycosylation heterogeneity accounts for the range within each form.

Does this antibody recognize both pro-MMP-1 and active MMP-1?

This polyclonal antibody is raised against a region spanning the catalytic and hemopexin domains, which are retained in both the zymogen and proteolytically activated forms. It should therefore detect both pro-MMP-1 and active MMP-1. If your experiment requires discrimination between activation states, run samples under reducing conditions and distinguish bands by molecular weight. For studies specifically tracking activation, consider pairing this antibody with assays that measure enzymatic activity or use activation-state-specific antibodies if differential detection rather than total MMP-1 quantification is your goal.

What starting dilution should I use for Western blot with this MMP-1 antibody?

We recommend starting at 1:1000 dilution for Western blot, which has been validated in-house with human samples. Optimal dilution depends on MMP-1 expression level in your sample, transfer efficiency, and detection system sensitivity. Fibroblasts stimulated with IL-1β or PMA, and certain tumor cell lines, express MMP-1 at readily detectable levels at 1:1000. For low-expressing samples or serum-free conditioned media, you may need to concentrate samples or use dilutions as high as 1:500. For initial optimization, run a dilution series between 1:500 and 1:2000.

Will this antibody work with rat or mouse samples?

This antibody is validated for human MMP-1 and predicted to cross-react with rat, non-human primate, dog, and pig based on epitope sequence conservation. It is not expected to detect mouse MMP-1. Mice lack a direct MMP-1 orthologue; the functional equivalent is MMP-13 (collagenase-3), which has divergent sequence. If you are working with mouse tissue or cells, you will need an MMP-13-specific antibody. For rat samples, test at the recommended 1:1000 dilution but include a positive control such as stimulated rat fibroblast lysate to confirm reactivity in your hands.

What positive control should I use to validate MMP-1 detection?

Human dermal fibroblasts or HT-1080 fibrosarcoma cells stimulated with phorbol 12-myristate 13-acetate (PMA, 10-50 ng/ml, 24-48 hours) serve as robust positive controls, as both cell types upregulate and secrete MMP-1. Collect conditioned serum-free media or prepare whole-cell lysates. Recombinant human pro-MMP-1 or active MMP-1 protein provides an alternative, allowing you to confirm antibody specificity and estimate detection sensitivity. Unstimulated fibroblasts or non-collagenase-expressing cell lines such as HEK293 work as negative controls, though low basal MMP-1 may still be detectable.

Can I use this antibody for immunohistochemistry on formalin-fixed paraffin-embedded tissue?

Triple Point Biologics antibodies are validated for Western blot; IHC application data is in progress. This MMP-1 antibody may perform in formalin-fixed paraffin-embedded sections. Antigen retrieval is typically required; citrate buffer (pH 6.0) heat-induced epitope retrieval is a standard starting point for MMP antibodies. MMP-1 is expressed by fibroblasts, keratinocytes, and infiltrating macrophages, often at sites of tissue remodeling, inflammation, or tumor invasion. Expect cytoplasmic and secreted extracellular staining. Optimize dilution empirically, starting around 1:100 to 1:200, as IHC generally requires higher antibody concentrations than Western blot.

How should I store this antibody and what is the expected shelf life?

Store the antibody at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titre and increase aggregation. Once thawed, an aliquot can be held at 4°C for up to one month for convenient daily use. Do not store diluted antibody in blocking buffer for extended periods. Lyophilized or glycerol-stabilized formulations have multi-year shelf life at -20°C; refer to the datasheet for your specific lot. If you observe increased background or loss of signal over time, discard the working aliquot and thaw a fresh one.

Should I expect to see multiple bands on Western blot, and how do I interpret them?

Yes, multiple bands are common with MMP-1. The proenzyme migrates at 52-57 kDa, and the active form at 41-45 kDa after propeptide cleavage. Depending on sample source, you may also detect intermediate processing forms or complexes with tissue inhibitors of metalloproteinases (TIMPs), which shift mobility. If you see higher-molecular-weight bands, consider that MMP-1 can form dimers or bind TIMP-1. Running samples under reducing conditions and including a deglycosylation step with PNGase F can help resolve ambiguous bands. Recombinant standards run in parallel lanes simplify interpretation.

Western blot validation for RP-MMP1 — 1 panel across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

MMP-1: Carboxyterminal end — WB validation
WB · Panel 1 MMP-1: Carboxyterminal end

Custom validation studies available on request — contact us.

Also known as:

  • MMP-1
  • MMP1
  • Interstitial collagenase
  • Fibroblast collagenase
  • Matrix metalloproteinase-1
  • EC 3.4.24.7
  • CLG
  • Collagenase-1
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →